# US 2016/0249593 A1 · Non-Mammalian RAS Transgenic Animal Model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0249593 A1
- Document ID: US20160249593A1
- Status: Published application
- Kind: A1
- Application number: 14/911,101
- Filed: 2014-08-19
- Published: 2016-09-01
- Earliest claimed: 2013-08-20
- Assignees: Tosk, Inc.
- Applicants: Tosk, Inc.
- Inventors: Travis Karg; William A. Garland; Steve Yanofsky
- Web page: https://patentgrep.com/patent/US20160249593A1

## CPC

- A01K 67/68: Genetically modified insects
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A01K 2217/052: inducing gain of function
- A01K 2227/706: Insects, e.g. Drosophila melanogaster, medfly
- A01K 2267/0331: Animal model for proliferative diseases
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.

## Claims

### Claim 1

A non-mammalian mutant animal, wherein said animal comprises a RAS transgene.

### Claim 2 (depends on 1)

The non-mammalian mutant animal according to claim 1, wherein the RAS transgene is a kRAS transgene.

### Claim 3 (depends on 2)

The non-mammalian mutant animal according to claim 2, wherein the kRAS transgene is a human kRAS transgene.

### Claim 4 (depends on 3)

The non-mammalian mutant animal according to claim 3, wherein the human kRAS transgene comprises a point mutation.

### Claim 5 (depends on 1)

The non-mammalian mutant animal according to claim 1, wherein the animal is an invertebrate.

### Claim 6 (depends on 5)

The non-mammalian mutant animal according to claim 5, wherein the invertebrate is an insect.

### Claim 7 (depends on 6)

The non-mammalian mutant animal according to claim 6, wherein the insect is a fly.

### Claim 8 (depends on 7)

The non-mammalian mutant animal according to claim 7, wherein the fly is a member of the family Drosophilidae.

### Claim 9 (depends on 8)

The non-mammalian mutant animal according to claim 8, wherein the fly is a Drosophila melanogaster.

### Claim 10 (depends on 1)

The non-mammalian mutant animal according to claim 1, wherein the transgene is ubiquitously expressed.

### Claim 11 (depends on 1)

The non-mammalian mutant animal according to claim 1, wherein the transgene is expressed in a tissue specific manner.

### Claim 12 (depends on 11)

The non-mammalian mutant animal according to claim 11, wherein the transgene is expressed in wing-tissue.

### Claim 13 (depends on 1)

The non-mammalian mutant animal according to claim 1, wherein the transgene is expressed in a developmental specific manner.

### Claim 14 (depends on 1)

A method of screening a compound for activity with respect to a cellular proliferative disease, the method comprising:
administering the compound to a non-mammalian transgenic animal according to claim 1; and
observing the effect of the compound on the non-mammalian transgenic animal.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the method comprises: feeding a plurality of compounds to a plurality of non-mammalian transgenic animals in a manner sufficient to ensure that each animal is fed only a single type compound from the plurality of compounds; and
observing the effect of said compounds on the plurality of animals.